Back to results

CompletedPhase 2

Study of Safety, Tolerability and Pharmacokinetics of Serelaxin in Japanese Acute Heart Failure (AHF) Patients

NCT02002702

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

Novartis Investigative Site

Seto, Aichi-ken, Japan

+14 additional locations

View on ClinicalTrials.gov

Save this trial

Quick facts

Start date: 2014-01
Enrollment: 46 participants
Sponsor: Novartis Pharmaceuticals
Purpose: treatment

Locations (15)

Novartis Investigative SiteSeto, Aichi-ken, Japan
Novartis Investigative SiteFukuoka, Fukuoka, Japan
Novartis Investigative SiteIizuka, Fukuoka, Japan
Novartis Investigative SiteHiroshima, Hiroshima, Japan
Novartis Investigative SiteAmagasaki, Hyōgo, Japan
Novartis Investigative SiteHigashiibaraki-gun, Ibaraki, Japan
Novartis Investigative SiteKanazawa, Ishikawa-ken, Japan
Novartis Investigative SiteKawasaki, Kanagawa, Japan
Novartis Investigative SiteYokohama, Kanagawa, Japan
Novartis Investigative SiteSendai, Miyagi, Japan
Novartis Investigative SiteUeda, Nagano, Japan
Novartis Investigative SiteOsaka, Osaka, Japan
Novartis Investigative SiteSayama, Saitama, Japan
Novartis Investigative SiteKomatsushimachō, Tokushima, Japan
Novartis Investigative SiteItabashi-ku, Tokyo, Japan

Study of Safety, Tolerability and Pharmacokinetics of Serelaxin in Japanese Acute Heart Failure (AHF) Patients — TrialFind